ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000C99

Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity

Identifieur interne : 000C99 ( PascalFrancis/Corpus ); précédent : 000C98; suivant : 000D00

Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity

Auteurs : S. S. Gill ; R. W. Mueller ; P. F. Mcguire ; O. M. Pulido

Source :

Toxicologic pathology [ 0192-6233 ] ; 2000.

RBID : Pascal:00-0268861

Descripteurs français

Pascal (Inist)
- Récepteur glutamate, Article synthèse, Site action, Aminoacide excitateur, Soustype, Récepteur NMDA, Localisation, Organe, Immunochimie, Foie, Poumon, Rein, Rate, Testicule, Sous-unité mGluR2, Sous unité mGluR3, Sous-unité NMDA R1.

English descriptors

KwdEn :
- Excitatory aminoacid, Glutamate receptor, Immunochemistry, Kidney, Liver, Localization, Lung, NMDA receptor, Organ, Review, Site of action, Spleen, Subtype, Testicle.

Abstract

Glutamate receptors (GluRs) are ubiquitously present in the central nervous system (CNS) as the major mediators of excitatory neurotransmission and excitotoxicity. Neural injury associated with trauma, stroke, epilepsy, and many neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's diseases and amyotrophic lateral sclerosis may be mediated by excessive activation of GluRs. Neurotoxicity associated with excitatory amino acids encountered in food, such as domoic acid and monosodium glutamate, has also been linked to GluRs. Less is known about GluRs outside the CNS. Recent observations suggest that several subtypes of GluRs are widely distributed in peripheral tissues. Using immunochemical and molecular techniques, the presence of GluR subtypes was demonstrated in the rat and monkey heart, with preferential distribution within the conducting system, nerve terminals, and cardiac ganglia. GluR subtypes NMDAR 1,GluR 2/3, and mGluR 2/3 are also present in kidney, liver, lung, spleen, and testis. Further investigations are needed to assess the role of these receptors in peripheral tissues and their importance in the toxicity of excitatory compounds. Therefore, food safety assessment and neurobiotechnology focusing on drugs designed to interact with GluRs should consider these tissues as potential target/effector sites.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0192-6233`
A03		`1`		`@0 Toxicol. pathol.`
A05				`@2 28`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity`
A11	`01`	`1`		`@1 GILL (S. S.)`
A11	`02`	`1`		`@1 MUELLER (R. W.)`
A11	`03`	`1`		`@1 MCGUIRE (P. F.)`
A11	`04`	`1`		`@1 PULIDO (O. M.)`
A14	`01`			`@1 Pathology Section, Toxicology Research Division, Bureau Chemical Safety, Health Protection Branch, Health Canada @2 Ottawa, Ontario, K1A 0L2 @3 CAN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A20				`@1 277-284`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 21944 @5 354000082296690070`
A44				`@0 0000 @1 © 2000 INIST-CNRS. All rights reserved.`
A45				`@0 43 ref.`
A47	`01`	`1`		`@0 00-0268861`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Toxicologic pathology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Glutamate receptors (GluRs) are ubiquitously present in the central nervous system (CNS) as the major mediators of excitatory neurotransmission and excitotoxicity. Neural injury associated with trauma, stroke, epilepsy, and many neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's diseases and amyotrophic lateral sclerosis may be mediated by excessive activation of GluRs. Neurotoxicity associated with excitatory amino acids encountered in food, such as domoic acid and monosodium glutamate, has also been linked to GluRs. Less is known about GluRs outside the CNS. Recent observations suggest that several subtypes of GluRs are widely distributed in peripheral tissues. Using immunochemical and molecular techniques, the presence of GluR subtypes was demonstrated in the rat and monkey heart, with preferential distribution within the conducting system, nerve terminals, and cardiac ganglia. GluR subtypes NMDAR 1,GluR 2/3, and mGluR 2/3 are also present in kidney, liver, lung, spleen, and testis. Further investigations are needed to assess the role of these receptors in peripheral tissues and their importance in the toxicity of excitatory compounds. Therefore, food safety assessment and neurobiotechnology focusing on drugs designed to interact with GluRs should consider these tissues as potential target/effector sites.
C02	`01`	`X`		`@0 002A04F03C`
C03	`01`	`X`	`FRE`	`@0 Récepteur glutamate @5 01`
C03	`01`	`X`	`ENG`	`@0 Glutamate receptor @5 01`
C03	`01`	`X`	`SPA`	`@0 Receptor glutámato @5 01`
C03	`02`	`X`	`FRE`	`@0 Article synthèse @5 04`
C03	`02`	`X`	`ENG`	`@0 Review @5 04`
C03	`02`	`X`	`SPA`	`@0 Artículo síntesis @5 04`
C03	`03`	`X`	`FRE`	`@0 Site action @5 07`
C03	`03`	`X`	`ENG`	`@0 Site of action @5 07`
C03	`03`	`X`	`SPA`	`@0 Lugar acción @5 07`
C03	`04`	`X`	`FRE`	`@0 Aminoacide excitateur @5 10`
C03	`04`	`X`	`ENG`	`@0 Excitatory aminoacid @5 10`
C03	`04`	`X`	`SPA`	`@0 Aminoácido excitador @5 10`
C03	`05`	`X`	`FRE`	`@0 Soustype @5 11`
C03	`05`	`X`	`ENG`	`@0 Subtype @5 11`
C03	`05`	`X`	`SPA`	`@0 Subtipo @5 11`
C03	`06`	`X`	`FRE`	`@0 Récepteur NMDA @5 12`
C03	`06`	`X`	`ENG`	`@0 NMDA receptor @5 12`
C03	`06`	`X`	`SPA`	`@0 Receptor NMDA @5 12`
C03	`07`	`X`	`FRE`	`@0 Localisation @5 13`
C03	`07`	`X`	`ENG`	`@0 Localization @5 13`
C03	`07`	`X`	`SPA`	`@0 Localización @5 13`
C03	`08`	`X`	`FRE`	`@0 Organe @5 14`
C03	`08`	`X`	`ENG`	`@0 Organ @5 14`
C03	`08`	`X`	`SPA`	`@0 Organo @5 14`
C03	`09`	`X`	`FRE`	`@0 Immunochimie @5 15`
C03	`09`	`X`	`ENG`	`@0 Immunochemistry @5 15`
C03	`09`	`X`	`SPA`	`@0 Inmunoquímica @5 15`
C03	`10`	`X`	`FRE`	`@0 Foie @5 16`
C03	`10`	`X`	`ENG`	`@0 Liver @5 16`
C03	`10`	`X`	`SPA`	`@0 Hígado @5 16`
C03	`11`	`X`	`FRE`	`@0 Poumon @5 17`
C03	`11`	`X`	`ENG`	`@0 Lung @5 17`
C03	`11`	`X`	`SPA`	`@0 Pulmón @5 17`
C03	`12`	`X`	`FRE`	`@0 Rein @5 18`
C03	`12`	`X`	`ENG`	`@0 Kidney @5 18`
C03	`12`	`X`	`SPA`	`@0 Riñón @5 18`
C03	`13`	`X`	`FRE`	`@0 Rate @5 19`
C03	`13`	`X`	`ENG`	`@0 Spleen @5 19`
C03	`13`	`X`	`SPA`	`@0 Bazo @5 19`
C03	`14`	`X`	`FRE`	`@0 Testicule @5 20`
C03	`14`	`X`	`ENG`	`@0 Testicle @5 20`
C03	`14`	`X`	`SPA`	`@0 Testículo @5 20`
C03	`15`	`X`	`FRE`	`@0 Sous-unité mGluR2 @4 INC @5 86`
C03	`16`	`X`	`FRE`	`@0 Sous unité mGluR3 @4 INC @5 87`
C03	`17`	`X`	`FRE`	`@0 Sous-unité NMDA R1 @4 INC @5 89`
N21				`@1 185`

Format Inist (serveur)

NO :	PASCAL 00-0268861 INIST
ET :	Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity
AU :	GILL (S. S.); MUELLER (R. W.); MCGUIRE (P. F.); PULIDO (O. M.)
AF :	Pathology Section, Toxicology Research Division, Bureau Chemical Safety, Health Protection Branch, Health Canada/Ottawa, Ontario, K1A 0L2/Canada (1 aut., 2 aut., 3 aut., 4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Toxicologic pathology; ISSN 0192-6233; Etats-Unis; Da. 2000; Vol. 28; No. 2; Pp. 277-284; Bibl. 43 ref.
LA :	Anglais
EA :	Glutamate receptors (GluRs) are ubiquitously present in the central nervous system (CNS) as the major mediators of excitatory neurotransmission and excitotoxicity. Neural injury associated with trauma, stroke, epilepsy, and many neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's diseases and amyotrophic lateral sclerosis may be mediated by excessive activation of GluRs. Neurotoxicity associated with excitatory amino acids encountered in food, such as domoic acid and monosodium glutamate, has also been linked to GluRs. Less is known about GluRs outside the CNS. Recent observations suggest that several subtypes of GluRs are widely distributed in peripheral tissues. Using immunochemical and molecular techniques, the presence of GluR subtypes was demonstrated in the rat and monkey heart, with preferential distribution within the conducting system, nerve terminals, and cardiac ganglia. GluR subtypes NMDAR 1,GluR 2/3, and mGluR 2/3 are also present in kidney, liver, lung, spleen, and testis. Further investigations are needed to assess the role of these receptors in peripheral tissues and their importance in the toxicity of excitatory compounds. Therefore, food safety assessment and neurobiotechnology focusing on drugs designed to interact with GluRs should consider these tissues as potential target/effector sites.
CC :	002A04F03C
FD :	Récepteur glutamate; Article synthèse; Site action; Aminoacide excitateur; Soustype; Récepteur NMDA; Localisation; Organe; Immunochimie; Foie; Poumon; Rein; Rate; Testicule; Sous-unité mGluR2; Sous unité mGluR3; Sous-unité NMDA R1
ED :	Glutamate receptor; Review; Site of action; Excitatory aminoacid; Subtype; NMDA receptor; Localization; Organ; Immunochemistry; Liver; Lung; Kidney; Spleen; Testicle
SD :	Receptor glutámato; Artículo síntesis; Lugar acción; Aminoácido excitador; Subtipo; Receptor NMDA; Localización; Organo; Inmunoquímica; Hígado; Pulmón; Riñón; Bazo; Testículo
LO :	INIST-21944.354000082296690070
ID :	00-0268861

Links to Exploration step

Pascal:00-0268861

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity</title>
<author><name sortKey="Gill, S S" sort="Gill, S S" uniqKey="Gill S" first="S. S." last="Gill">S. S. Gill</name>
<affiliation><inist:fA14 i1="01"><s1>Pathology Section, Toxicology Research Division, Bureau Chemical Safety, Health Protection Branch, Health Canada</s1>
<s2>Ottawa, Ontario, K1A 0L2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mueller, R W" sort="Mueller, R W" uniqKey="Mueller R" first="R. W." last="Mueller">R. W. Mueller</name>
<affiliation><inist:fA14 i1="01"><s1>Pathology Section, Toxicology Research Division, Bureau Chemical Safety, Health Protection Branch, Health Canada</s1>
<s2>Ottawa, Ontario, K1A 0L2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcguire, P F" sort="Mcguire, P F" uniqKey="Mcguire P" first="P. F." last="Mcguire">P. F. Mcguire</name>
<affiliation><inist:fA14 i1="01"><s1>Pathology Section, Toxicology Research Division, Bureau Chemical Safety, Health Protection Branch, Health Canada</s1>
<s2>Ottawa, Ontario, K1A 0L2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pulido, O M" sort="Pulido, O M" uniqKey="Pulido O" first="O. M." last="Pulido">O. M. Pulido</name>
<affiliation><inist:fA14 i1="01"><s1>Pathology Section, Toxicology Research Division, Bureau Chemical Safety, Health Protection Branch, Health Canada</s1>
<s2>Ottawa, Ontario, K1A 0L2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0268861</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0268861 INIST</idno>
<idno type="RBID">Pascal:00-0268861</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C99</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity</title>
<author><name sortKey="Gill, S S" sort="Gill, S S" uniqKey="Gill S" first="S. S." last="Gill">S. S. Gill</name>
<affiliation><inist:fA14 i1="01"><s1>Pathology Section, Toxicology Research Division, Bureau Chemical Safety, Health Protection Branch, Health Canada</s1>
<s2>Ottawa, Ontario, K1A 0L2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mueller, R W" sort="Mueller, R W" uniqKey="Mueller R" first="R. W." last="Mueller">R. W. Mueller</name>
<affiliation><inist:fA14 i1="01"><s1>Pathology Section, Toxicology Research Division, Bureau Chemical Safety, Health Protection Branch, Health Canada</s1>
<s2>Ottawa, Ontario, K1A 0L2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcguire, P F" sort="Mcguire, P F" uniqKey="Mcguire P" first="P. F." last="Mcguire">P. F. Mcguire</name>
<affiliation><inist:fA14 i1="01"><s1>Pathology Section, Toxicology Research Division, Bureau Chemical Safety, Health Protection Branch, Health Canada</s1>
<s2>Ottawa, Ontario, K1A 0L2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pulido, O M" sort="Pulido, O M" uniqKey="Pulido O" first="O. M." last="Pulido">O. M. Pulido</name>
<affiliation><inist:fA14 i1="01"><s1>Pathology Section, Toxicology Research Division, Bureau Chemical Safety, Health Protection Branch, Health Canada</s1>
<s2>Ottawa, Ontario, K1A 0L2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Toxicologic pathology</title>
<title level="j" type="abbreviated">Toxicol. pathol.</title>
<idno type="ISSN">0192-6233</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Toxicologic pathology</title>
<title level="j" type="abbreviated">Toxicol. pathol.</title>
<idno type="ISSN">0192-6233</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Excitatory aminoacid</term>
<term>Glutamate receptor</term>
<term>Immunochemistry</term>
<term>Kidney</term>
<term>Liver</term>
<term>Localization</term>
<term>Lung</term>
<term>NMDA receptor</term>
<term>Organ</term>
<term>Review</term>
<term>Site of action</term>
<term>Spleen</term>
<term>Subtype</term>
<term>Testicle</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Récepteur glutamate</term>
<term>Article synthèse</term>
<term>Site action</term>
<term>Aminoacide excitateur</term>
<term>Soustype</term>
<term>Récepteur NMDA</term>
<term>Localisation</term>
<term>Organe</term>
<term>Immunochimie</term>
<term>Foie</term>
<term>Poumon</term>
<term>Rein</term>
<term>Rate</term>
<term>Testicule</term>
<term>Sous-unité mGluR2</term>
<term>Sous unité mGluR3</term>
<term>Sous-unité NMDA R1</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Glutamate receptors (GluRs) are ubiquitously present in the central nervous system (CNS) as the major mediators of excitatory neurotransmission and excitotoxicity. Neural injury associated with trauma, stroke, epilepsy, and many neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's diseases and amyotrophic lateral sclerosis may be mediated by excessive activation of GluRs. Neurotoxicity associated with excitatory amino acids encountered in food, such as domoic acid and monosodium glutamate, has also been linked to GluRs. Less is known about GluRs outside the CNS. Recent observations suggest that several subtypes of GluRs are widely distributed in peripheral tissues. Using immunochemical and molecular techniques, the presence of GluR subtypes was demonstrated in the rat and monkey heart, with preferential distribution within the conducting system, nerve terminals, and cardiac ganglia. GluR subtypes NMDAR 1,GluR 2/3, and mGluR 2/3 are also present in kidney, liver, lung, spleen, and testis. Further investigations are needed to assess the role of these receptors in peripheral tissues and their importance in the toxicity of excitatory compounds. Therefore, food safety assessment and neurobiotechnology focusing on drugs designed to interact with GluRs should consider these tissues as potential target/effector sites.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0192-6233</s0>
</fA01>
<fA03 i2="1"><s0>Toxicol. pathol.</s0>
</fA03>
<fA05><s2>28</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GILL (S. S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MUELLER (R. W.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MCGUIRE (P. F.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PULIDO (O. M.)</s1>
</fA11>
<fA14 i1="01"><s1>Pathology Section, Toxicology Research Division, Bureau Chemical Safety, Health Protection Branch, Health Canada</s1>
<s2>Ottawa, Ontario, K1A 0L2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>277-284</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>21944</s2>
<s5>354000082296690070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>43 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0268861</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Toxicologic pathology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Glutamate receptors (GluRs) are ubiquitously present in the central nervous system (CNS) as the major mediators of excitatory neurotransmission and excitotoxicity. Neural injury associated with trauma, stroke, epilepsy, and many neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's diseases and amyotrophic lateral sclerosis may be mediated by excessive activation of GluRs. Neurotoxicity associated with excitatory amino acids encountered in food, such as domoic acid and monosodium glutamate, has also been linked to GluRs. Less is known about GluRs outside the CNS. Recent observations suggest that several subtypes of GluRs are widely distributed in peripheral tissues. Using immunochemical and molecular techniques, the presence of GluR subtypes was demonstrated in the rat and monkey heart, with preferential distribution within the conducting system, nerve terminals, and cardiac ganglia. GluR subtypes NMDAR 1,GluR 2/3, and mGluR 2/3 are also present in kidney, liver, lung, spleen, and testis. Further investigations are needed to assess the role of these receptors in peripheral tissues and their importance in the toxicity of excitatory compounds. Therefore, food safety assessment and neurobiotechnology focusing on drugs designed to interact with GluRs should consider these tissues as potential target/effector sites.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A04F03C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Récepteur glutamate</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Glutamate receptor</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Receptor glutámato</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Review</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Site action</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Site of action</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Lugar acción</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Aminoacide excitateur</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Excitatory aminoacid</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Aminoácido excitador</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Soustype</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Subtype</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Subtipo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Récepteur NMDA</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>NMDA receptor</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Receptor NMDA</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Localisation</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Localization</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Localización</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Organe</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Organ</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Organo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Immunochimie</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Immunochemistry</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Inmunoquímica</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Foie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Liver</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hígado</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Poumon</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Lung</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Pulmón</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Rein</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Kidney</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Riñón</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Rate</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Spleen</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Bazo</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Testicule</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Testicle</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Testículo</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Sous-unité mGluR2</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Sous unité mGluR3</s0>
<s4>INC</s4>
<s5>87</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Sous-unité NMDA R1</s0>
<s4>INC</s4>
<s5>89</s5>
</fC03>
<fN21><s1>185</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 00-0268861 INIST</NO>
<ET>Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity</ET>
<AU>GILL (S. S.); MUELLER (R. W.); MCGUIRE (P. F.); PULIDO (O. M.)</AU>
<AF>Pathology Section, Toxicology Research Division, Bureau Chemical Safety, Health Protection Branch, Health Canada/Ottawa, Ontario, K1A 0L2/Canada (1 aut., 2 aut., 3 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Toxicologic pathology; ISSN 0192-6233; Etats-Unis; Da. 2000; Vol. 28; No. 2; Pp. 277-284; Bibl. 43 ref.</SO>
<LA>Anglais</LA>
<EA>Glutamate receptors (GluRs) are ubiquitously present in the central nervous system (CNS) as the major mediators of excitatory neurotransmission and excitotoxicity. Neural injury associated with trauma, stroke, epilepsy, and many neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's diseases and amyotrophic lateral sclerosis may be mediated by excessive activation of GluRs. Neurotoxicity associated with excitatory amino acids encountered in food, such as domoic acid and monosodium glutamate, has also been linked to GluRs. Less is known about GluRs outside the CNS. Recent observations suggest that several subtypes of GluRs are widely distributed in peripheral tissues. Using immunochemical and molecular techniques, the presence of GluR subtypes was demonstrated in the rat and monkey heart, with preferential distribution within the conducting system, nerve terminals, and cardiac ganglia. GluR subtypes NMDAR 1,GluR 2/3, and mGluR 2/3 are also present in kidney, liver, lung, spleen, and testis. Further investigations are needed to assess the role of these receptors in peripheral tissues and their importance in the toxicity of excitatory compounds. Therefore, food safety assessment and neurobiotechnology focusing on drugs designed to interact with GluRs should consider these tissues as potential target/effector sites.</EA>
<CC>002A04F03C</CC>
<FD>Récepteur glutamate; Article synthèse; Site action; Aminoacide excitateur; Soustype; Récepteur NMDA; Localisation; Organe; Immunochimie; Foie; Poumon; Rein; Rate; Testicule; Sous-unité mGluR2; Sous unité mGluR3; Sous-unité NMDA R1</FD>
<ED>Glutamate receptor; Review; Site of action; Excitatory aminoacid; Subtype; NMDA receptor; Localization; Organ; Immunochemistry; Liver; Lung; Kidney; Spleen; Testicle</ED>
<SD>Receptor glutámato; Artículo síntesis; Lugar acción; Aminoácido excitador; Subtipo; Receptor NMDA; Localización; Organo; Inmunoquímica; Hígado; Pulmón; Riñón; Bazo; Testículo</SD>
<LO>INIST-21944.354000082296690070</LO>
<ID>00-0268861</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C99 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000C99 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:00-0268861
   |texte=   Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity

Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri